Gain Therapeutics receives Australian approval to start Phase 1b trial of GT-02287 for Parkinson's disease

Gain Therapeutics, Inc.

Australian ethics approval obtained for Phase 1b trial of GT-02287 in GBA1-PD and idiopathic PD patients.
Trial will dose 13.5 mg/kg/day for three months; primary endpoint safety/tolerability; secondary endpoints include biomarkers.
Enrollment expected to complete spring 2025; data anticipated mid-2025.
Phase 1 in healthy volunteers showed safety, CNS exposure, and >50% increase in GCase activity (statistically significant).
Company plans Phase 2 preparation after Phase 1b results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.